Portfolio Description

Project Details


Year: 2019

Timeframe: 6 months

Main Service: Content Marketing

Return Over Investment: 92% 

ENZYCHEM Content Marketing

Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18 (Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications. The company is also developing EC-18 in fibrotic diseases such as nonalcoholic steatohepatitis (NASH), and in severe respiratory diseases as a potential therapy for COVID-19. EC-18, or PLAG, is a naturally synthesized substance, derived from an active ingredient in Sika deer antlers. Our pipeline candidates have the potential to be first-in-class therapies for use in combination or as monotherapy, in major areas of unmet medical need.

softglaze portfolio
softglaze portfolio
softglaze portfolio

Let’s Get in Touch

We’re interested in talking
about your business.